our commitment

Ebiotec is part of the Euroespes Group which, in its 30-year history, has carried out more than 150 research projects, resulting in 1600 scientific publications, several patents and the first World Guide to Pharmacogenomics.

Our institutional commitment is focused on 5 priority areas
  1. Genomic medicine applied to risk prediction and early diagnosis of prevalent neurodegenerative and cerebrovascular diseases.
  2. Pharmacogenomics applied to the personalization of pharmacological treatments.
  3. Development and production of nutraceutical bioproducts for the prevention and treatment of various pathologies.
  4. Dissemination of scientific knowledge.

Among our priorities is the search for efficient solutions to the serious problem of dementia (Alzheimer's disease and vascular dementia), stroke and other degenerative problems of the nervous system, such as Parkinson's disease.

 

All these disabling diseases of the nervous system are the primary target of our preventive and therapeutic programs through the development of vaccines and predictive medical genomics and pharmacogenomics programs applied to the specific needs of each individual.

0